Skip to main content
. Author manuscript; available in PMC: 2010 Nov 22.
Published in final edited form as: Diabetologia. 2008 Dec 23;52(3):385–393. doi: 10.1007/s00125-008-1239-x

Table 1.

Baseline characteristics of the study population by treatment group

Characteristic Placebo Salsalate p value
n 18 22
Men/women (n) 9/9 10/12 1.0
Ethnicity (W/N/H) 3/14/1 3/19/0 0.6
Age (years) 33 (8) 29 (7) 0.2
BMI (kg/m2) 38 (6) 37 (5) 0.7
Body fat (%) 38 (7) 38 (6) 0.9
Fasting plasma glucose (mmol/l) 5.06 (0.33) 5.11 (0.33) 0.9
2 h plasma glucose (mmol/l) 6.61 (1.83) 6.67 (1.17) 0.9
Fasting plasma insulin (pmol/l) 63 (49, 90) 80 (56, 104) 0.3
Basal EGP (μmol [kgEMBS]−1 min−1) 11 (2) 10 (2) 0.2
Clamp EGP (μmol [kgEMBS]−1 min−1) 0 (0, 3) 0 (0, 2) 0.8
Clamp Rd (μmol [kgEMBS]−1 min−1)a 16 (13, 20) 13 (11, 15) 0.09

Unless otherwise stated, data are means (SD) or medians (25th, 75th percentile)

a

Rd normalised for steady-state plasma glucose and serum insulin concentrations

p values were determined by Mantel–Haenszel test on categories, Student’s t test on means and Wilcoxon’s U test on medians; W, Whites; N, Native Americans; H, Hispanics

HHS Vulnerability Disclosure